期刊文献+

奈西雅预防治疗化疗所致胃肠道反应的临床研究 被引量:2

Efficacy of nasea injection in prevention and treatment of gastrointestinal reaction induced by chemotherapy
下载PDF
导出
摘要 目的:观察奈西雅防治化疗药物引起的胃肠道反应的疗效及其不良反应.方法:采用开放式的研究,对86例患者化疗同时给予奈西雅(0.3 mg,静脉推注,d1~d3),观察化疗不同时间其对食欲不振、恶心、呕吐等的预防和治疗作用.结果:奈西雅防治化疗药物尤其是顺铂和(或)表阿霉素的胃肠道不良反应有较好疗效,有效率分别为53.5%~90.6%;对顺铂引起的迟发性呕吐亦有一定的防治作用;不良反应轻,主要为便秘、头痛、口干、头重、发热感等.结论:奈西雅能有效防治化疗药物所致的胃肠道反应,疗效维持时间长,不良反应轻,为较好的化疗止吐剂. OBJECTIVE:To evaluate the efficacy and toxicity of Nasea in the prevention and treatment of gastrointestinal reaction induced by chemotherapy. METHODS: The study was an open clinical trial. Eighty-six patients received the injection of nasea while chemotherapy. The efficacy and side effects of nasea were evaluated at the same time. RESULTS: Nasea was effective in the control of anorexia, nausea and vomiting induced by anti-cancer drugs(especially for DDP and EPI ), the response rates were 53.5%-90.6% respectively. The side effects of nasea were constipation, headache, thirst feeling, head heaviness, fever feeling, etc. All of them were mild. CONCLUSIONS: Nasea can effectively prevent and treat the gastrointestinal reaction induced by chemotherapeutic agents. [
出处 《肿瘤防治杂志》 2005年第9期696-698,共3页 China Journal of Cancer Prevention and Treatment
关键词 癌/药物疗法 药物疗法/副作用 胃肠活动/药物疗法 carcinoma/drug therapy drug therapy/adverse effects gastrointestinal motility/drug therapy
  • 相关文献

参考文献5

  • 1张频,冯奉仪,何友兼,李宇红,周美珍,程刚,李琳.奈西雅注射剂预防化疗药物所致胃肠反应的临床研究[J].中华肿瘤杂志,2000,22(1):70-73. 被引量:17
  • 2Noda K, Ikeda M, Yoshida O, et al. Clinical phase Ⅲ study of YM060 injection on anti-cancer drug, cisplatin-induced nausea and vomiting [J]. Med Cons New-Remed, 1994,43(11) :2241-2255.
  • 3Fujihara A, Tanaka S, Suzuki M, et al. The effect of YM060, a novel 5-HT3 receptor antagonist, on 5-HT3 induced Bezold-Jarisch reflex in ferrets [J]. Clin Rep, 1994,28(8):2329-2335.
  • 4Fujihara A, Tanaka S, Suzuki M, et al. The effect of YM060, a novel 5 HT3 receptor antagonist, on cisplatin-induced emesis in ferrets [J]. Clin Rep,1994,28(8) :2337-2347.
  • 5Y K Kang, Y H Park, B Y Ryoo, et al. Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron [J]. J Int Med Res, 2002,30(2): 220- 229.

二级参考文献1

共引文献16

同被引文献10

  • 1Noda K,Ikeda M,Yoshida O,et al.Clinical phase Ⅲ study of YM060 injection on anti-cancer drug,cisplatin-reduced nausea and vomiting[J].Med Cons New-Remed,1994,43(11):2241-2255.
  • 2Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesi-ty, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for 3 years [ J ]. Curr Med Res Opin,2008,24 : 275 - 286.
  • 3Nauck MA, Duran S, KimD, et al. A comparison of twice - daily exenatide and hiphasic insulin aspart in patients with type 2 diabetes who were sub- optimally controlled with sulfonylurea and metformin: a non- inferiority study[J]. Diabetologia,2007,50:259 -267.
  • 4Gao Y, Yoon KH, Chuang LM, et al. Efficacy and safety of exenatide in pa- tients of Asian descent with type 2 diabetes inadequately controlled with metfonnin or metformin and asulphonylurea[J]. Diabetes Res Clin Pract, 2009,83 : 69 - 76.
  • 5Williams DL, Baskin DG, Schwartz MW. Evidence that intestinal glucagon - likepeptide - l plays aphysioligical role in satiety[J]. Endocrinology, 2009, 150:1 680 - 1 687.
  • 6Blonde L, Klein E, Han J, et al. Interim analysis of the effects of exenatide treatment on A1 C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patiems with type 2 diabetes[J]. Diabetes Obes Metab, 2006,8(4) :436 - 447.
  • 7Buse JB, Henry RR, Han J, et al. Effeets of exenatide(exendin- 4) on glycemic control_ over 30 weeks in sulfonylurea - treated patients with type 2 diabetes [ J ]. Diabetes Care, 2004,27 : 2 628 - 2 635.
  • 8Kendall DM, Riddle MC, Resenstock J, et al. Effects of exenatide (exendin- 4)Oil glyeemie control over 30 weeks in patients with type 2 diabetes treated with mefformin and a sulfonylurea[J]. Diabetes Care, 2005,28:1 083 - 1 091.
  • 9Deacon CF. Potential of liraglutide in the treatment of patients with type 2 diabetes [ J ]. Vasc Health Risk Manag, 2009,5 ( 1 ) : 199 - 211.
  • 10王培民,李浩,王宝胜,李建梅.盐酸雷莫司琼预防手术后恶心呕吐的临床观察[J].现代医药卫生,2003,19(7):871-871. 被引量:1

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部